[ad_1]
The Health Care and Social Insurance Agency (BPJS Health) decided to stop bad cancer chemotherapy trastuzumab ( Herceptin) and encouraged someone to take legal action.
The BPJS stopped covering trastuzumab for patients treated by the National Health Insurance Scheme (JKN-KIS) since April 1, arguing that the effectiveness of the drugs is not empirically proven.
Juniarti patients, 46, from East Jakarta have been denied access to drugs after being diagnosed with HER2 + bad cancer in May. After a mastectomy in June, his doctor was still giving trastuzumab. Knowing that trastuzumab is very important for survival, Juniarti and her husband Edy Haryadi decided to file a lawsuit against BPJS for refusing their access to the drug. . He will also sue President Joko Widodo for allowing BPJS to end coverage.
" According to applicable law, the head of the BPJS reports directly to the president.Only the president can stop the imprudent policy of BPJS […] .He could not wash his hands properly [dari hal ini] ", a Edy said.
"Without this drug, my wife can only survive for 1.5 years, but with medications she can have a life expectancy of more than 10 years
" her belief in drugs was inspired by Story of the life of Aryanthi Baramuli, head of the cancer information support center, who was diagnosed with the same type of cancer as Juniarti
"He said his organization had sent an official letter to the Clinical Advisory Board (DPK), questioning their recommendation that BPJS remove the drug, but the DPK did not respond.
" The company, especially patient organizations desperately needs the right information because this decision makes patients feel insecure "said Aryanthi.About meanwhile, BPJS affirms its decision to cross trastuzumab from a list of cancer drugs based on scientific research.
" DPK concluded that trastuzumab is unjustifiable for patients with bad cancer, " "Our commitment is to ensure that patients receive appropriate care based on their medical needs, "he said.
Nopie pointed out that the decision to eliminate trastuzumab will deny patients access to bad cancer treatment because alternative medicines recognized by the national list are still closed.
" The physician responsible for the patient will prescribe cancer treatment according to the patient's clinical condition He added:
Nopie added that BPJS involved the Ministry of Health, DPK and T (19659019) Oncologist Ronald Hokum says that trastuzumab is an effective treatment for early-stage bad cancer and stage 4 for metastatic bad cancer, adding that the drug is also on the list of essential drugs. from the World Health Organization.
Trastuzumab is a monoclonal antibody registered in the United States since 1998 as one of the HER2 + stage 4 bad cancer solutions [metastasis]. , drugs administered by injection with chemotherapy can inhibit the growth of cancer cells and stimulate the immune system response.
According to Ronald, trastuzumab costs around Rp 9, 8 million for a flaco n 440 milligrams, which would cost about 80 million rupees to patients for eight rounds of treatment
"Treatment of bad cancer to treat bad cancer HER2 + stage 4 mentioned in the 2017 Ministry of Health decision mentioning trastuzumab and lapatinib, so it is not accurate if BPJS says that there are many other remedies other than trastuzumab "he said.
Source link
